Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma: Clinical article Academic Article uri icon

Overview

MeSH Major

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Blood-Brain Barrier
  • Brain Neoplasms
  • Glioma

abstract

  • The authors conclude that SIACI of mannitol followed by bevacizumab (up to 15 mg/kg) for recurrent malignant glioma is safe and well tolerated. Magnetic resonance imaging shows that SIACI treatment with bevacizumab can lead to reduction in tumor area, volume, perfusion, and T2-weighted/FLAIR signal.

publication date

  • March 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3622705

Digital Object Identifier (DOI)

  • 10.3171/2010.9.JNS101223

PubMed ID

  • 20964595

Additional Document Info

start page

  • 624

end page

  • 32

volume

  • 114

number

  • 3